EIGRQ — Eiger Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00- $12.59m
- $28.27m
- $15.77m
Brief: Eiger Biopharmaceuticals Provides Update On Status Of Planned Peginterferon Lambda Covid-19 Emergency Use Authorization Application
Brief: Eiger Receives European Approval For Zokinvy
Brief: Eiger Appoints Senior HR, Organizational Executive Lisa Kelly-Croswell To Board
Brief: Eiger BioPharmaceuticals Announces New Data Supporting Broader Potential Of Avexitide In Patients With Post-Bariatric Hypoglycemia And Hyperinsulinemic Hypoglycemia After Gastrointestinal Surgeries
Brief: Eiger Biopharmaceuticals Announces Multiple Presentations At The European Association For The Study Of The Liver
Brief: Eiger Biopharmaceuticals Enters Into $75M Term Loan Agreement And $5M Stock Purchase Agreement With Innovatus Capital Partners To Refinance Existing Debt Facility And Further Strengthen Cash Position Ahead Of Key Milestones
Brief: Eiger Receives Positive CHMP Opinion For Zokinvy As A Treatment For Hutchinson-Gilford Progeria Syndrome And Processing-Deficient Progeroid Laminopathies
Brief: Eiger BioPharmaceuticals And AnGes Enter Partnership For Lonafarnib In Japan
Eiger BioPharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Eiger BioPharmaceuticals Reports Q1 Loss Per Share Of $0.64
Eiger BioPharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview
Brief: Eiger Reports Publication Of Positive Results Of Avexitide In Children With Congenital Hyperinsulinism
Brief: Eiger Biopharmaceuticals Enters Into Open Market Agreement To Offer And Sell Shares Of Up To $50 Mln
U.S. STOCKS ON THE MOVE-Amazon, Nutrien, Eiger BioPharma
Eiger BioPharma up as COVID therapy cuts hospitalization risk by 50% in study
Brief: Eiger's Single-Dose Peginterferon Lambda For Covid-19 Reduced Risk Of Hospitalization Or Er Visits By 50% In A Predominantly Vaccinated Population In Phase 3 Together Study
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Eiger Biopharmaceuticals Reports Fourth Quarter And Full Year 2021 Financial Results
Eiger BioPharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview